Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 99

Sort by

Sort Order Select

Journal Articles

Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas

Fatima Tuz Zahra, Faustine Ong, Moazzam Shahzad, Onyee Chan, Najla H. Al Ali, Jeffrey E Lancet, Alison R. Walker, David Sallman, Rami S. Komrokji, Seongseok Yun, Andrew T. Kuykendall, Eric Padron, Zhuoer Xie

Blood (2024) 144 (Supplement 1): 5190.

https://doi.org/10.1182/blood-2024-211740

Published: 2024

Journal Articles

Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms

Blood (2024) 144 (Supplement 1): 1048.

https://doi.org/10.1182/blood-2024-210830

Published: 2024

Journal Articles

Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes

David Sallman, Amy F McLemore, Rami S. Komrokji, Hany Elmariah, Andrew T. Kuykendall, Nelli Bejanyan, Onyee Chan, Rawan Faramand, Joseph A. Pidala, Sean J. Yoder, Lia Perez, Taiga Nishihori, Eric Padron, Hugo Francisco Fernandez, Jeffrey E Lancet, Asmita Mishra

Blood (2024) 144 (Supplement 1): 1046.

https://doi.org/10.1182/blood-2024-203903

Published: 2024

Journal Articles

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Nico Gagelmann, Barbara Mora, Filippo Branzanti, Alessandro Maria Vannucchi, Massimo Breccia, Giuseppe Alberto Maria Palumbo, Massimiliano Bonifacio, Erika Morsia, Elena Maria Elli, Mario Tiribelli, Giulia Benevolo, Mirko Farina, Fabrizio Pane, Roberto Massimo Lemoli, Giovanni Caocci, Alessia Tieghi, Gianni Binotto, Francesco Cavazzini, Bruno Martino, Alessandro Isidori, Margherita Maffioli, Elisa Rumi, Tiziano Barbui, Francisco Cervantes, Matteo Giovanni Della Porta, Andrew T. Kuykendall, Marianna Caramella, Alessandra Iurlo, Valerio De Stefano, Jean-Jacques Kiladjian, David Ross, Jason Gotlib, Timothy Devos, Marco Ruggeri, Richard T. Silver, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Christina Rautenberg, Marie Robin, Marie-Thérèse Rubio, Jaroslaw Maciejewski, Alessandro Rambaldi, Maria Chiara Finazzi, Andrea Bacigalupo, Patrizia Chiusolo, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kröger, Francesco Passamonti, Francesca Palandri

Blood (2024) 144 (Supplement 1): 245.

https://doi.org/10.1182/blood-2024-210804

Published: 2024

Journal Articles

A Phase 1 Study of CPX-351 Plus Gilteritinib in Relapsed or Refractory FLT3 -Mutated Acute Myeloid Leukemia

Onyee Chan, Kendra L. Sweet, Jhada-Kai Hunter, Somedeb Ball, Qianxing Mo, Zhuoer Xie, Seongseok Yun, Andrew T. Kuykendall, Eric Padron, Alison R. Walker, Rami S. Komrokji, Jeffrey E Lancet, David Sallman

Blood (2024) 144 (Supplement 1): 1520.

https://doi.org/10.1182/blood-2024-205977

Published: 2024

Journal Articles

Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience

Fatima Tuz Zahra, Faustine Ong, Daniel Walgenbach, Onyee Chan, Katherine Tobon, Jeffrey E Lancet, David Sallman, Rami S. Komrokji, Andrew T. Kuykendall, Eric Padron, Alison R. Walker, Zhuoer Xie, Seongseok Yun

Blood (2024) 144 (Supplement 1): 2415.

https://doi.org/10.1182/blood-2024-202576

Published: 2024

Journal Articles

Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of Imetelstat with Ruxolitinib in Patients with Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis (MF)

John O. Mascarenhas, Salman Otoukesh, Terrence Bradley, Bart L. Scott, Habte A. Yimer, Souria Dougherty, Lixian Peng, Fei Huang, Ying Wan, Faye M. Feller, Vivian Rodolf, Judy Ho, Tymara Berry, Andrew T. Kuykendall

Blood (2024) 144 (Supplement 1): 998.

https://doi.org/10.1182/blood-2024-203800

Published: 2024

Journal Articles

A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia

Andrew T. Kuykendall, Tania Jain, Abhay Singh, Kristen M. Pettit, Quan Lovette, Joan McFadden Cain, Tracy Ann Cinalli, Mary Gallagher, David Sallman, Qianxing Mo, Ling Zhang, Onyee Chan, Alison R. Walker, Zhuoer Xie, Jeffrey E Lancet, Maria Balasis, Seongseok Yun, Eric Padron, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 481.

https://doi.org/10.1182/blood-2024-210743

Published: 2024

Journal Articles

Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Marker in Myelodysplastic Syndromes

Rami S. Komrokji, Zena Komrokji, Najla H. Al Ali, Zhuoer Xie, Onyee Chan, Andrew T. Kuykendall, Joseph E. Jabbour, Alison R. Walker, Jeffrey E Lancet, Eric Padron, David Sallman

Blood (2024) 144 (Supplement 1): 3217.

https://doi.org/10.1182/blood-2024-205861

Published: 2024

Journal Articles

Prospective Evaluation of the Impact of Measurable Residual Disease (MRD) By Error Corrected Next-Generation Sequencing (NGS) with CPX-351 in Acute Myeloid Leukemia (AML)

David Sallman, Amy F McLemore, Onyee Chan, Andrew T. Kuykendall, Eric Padron, Zhuoer Xie, Alison R. Walker, David H Spencer, Rami S. Komrokji, Jeffrey E Lancet, Meagan Jacoby

Blood (2024) 144 (Supplement 1): 4332.

https://doi.org/10.1182/blood-2024-205211

Published: 2024

Journal Articles

Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies

Jan Philipp Bewersdorf, Xiaoli Mi, Bin Lu, Andrew T. Kuykendall, David Sallman, Manish Patel, Don A. Stevens, Alexander Philipovskiy, Grerk Sutamtewagul, Lucia Masarova, Gina Keiffer, Amit Verma, Neha Bhagwat, Diane Heiser, Sunhee Ro, Wan-Jen Hong, Omar Abdel-Wahab, Eytan M. Stein

Blood (2024) 144 (Supplement 1): 3215.

https://doi.org/10.1182/blood-2024-198495

Published: 2024

Journal Articles

The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS

Ziad Abuhelwa, Najla H. Al Ali, Zhuoer Xie, Onyee Chan, Seongseok Yun, Andrew T. Kuykendall, Alison R. Walker, Jeffrey E Lancet, Eric Padron, David Sallman, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 4589.

https://doi.org/10.1182/blood-2024-204064

Published: 2024

Journal Articles

Retrospective Real-World Analysis of Survival Outcomes in Patients with Myelofibrosis and New or Worsening Anemia Treated with Ruxolitinib in the United States

Andrew T. Kuykendall, Francesca Palandri, Shiyuan Zhang, Tom Liu, Mirko Fillbrunn, Adina Zhang, Gautam Sajeev, James Signorovitch, Dwaipayan Patnaik, Aaron T. Gerds

Blood (2024) 144 (Supplement 1): 3804.

https://doi.org/10.1182/blood-2024-205380

Published: 2024

Journal Articles

IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD)

Rami S. Komrokji, Najla H. Al Ali, Zhuoer Xie, Zena Komrokji, Joseph E. Jabbour, Onyee Chan, Seongseok Yun, Andrew T. Kuykendall, Alison R. Walker, Jeffrey E Lancet, Eric Padron, David Sallman

Blood (2024) 144 (Supplement 1): 3228.

https://doi.org/10.1182/blood-2024-204167

Published: 2024

Journal Articles

Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin

Blood (2024) 144 (Supplement 1): 4578.

https://doi.org/10.1182/blood-2024-210599

Published: 2024

Journal Articles

Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes

Jeremy V. DiGennaro, George Concepcion, Najla H. Al Ali, Onyee Chan, Alison R. Walker, Zhuoer Xie, Eric Padron, Jeffrey E Lancet, David Sallman, Ashwin Kishtagari, Pankit Vachhani, John O. Mascarenhas, Rami S. Komrokji, Andrew T. Kuykendall

Blood (2024) 144 (Supplement 1): 4561.

https://doi.org/10.1182/blood-2024-202579

Published: 2024

Journal Articles

Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)

Aaron T. Gerds, Andrew T. Kuykendall, Marina Kremyanskaya, Ellen K. Ritchie, Jason Gotlib, Jeanne Palmer, Kristen M. Pettit, Victor Priego, Uttam Kumar Nath, Abdulraheem Yacoub, Arkapal Bandyopadhyay, Suneel Gupta, Sarita Khanna, Arturo Molina, Naveen Pemmaraju

Blood (2024) 144 (Supplement 1): 4559.

https://doi.org/10.1182/blood-2024-197985

Published: 2024

Journal Articles

Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia

Onyee Chan, Kendra L. Sweet, Chetasi Talati, Fatima Tuz Zahra, Lisa Ann Nardelli, Jatinder K. Lamba, Jongphil Kim, Jinming Song, Zhuoer Xie, Seongseok Yun, Andrew T. Kuykendall, Eric Padron, Alison R. Walker, Rami S. Komrokji, Jeffrey E Lancet, David Sallman

Blood (2024) 144 (Supplement 1): 4270.

https://doi.org/10.1182/blood-2024-206161

Published: 2024

Journal Articles

Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis

Blood (2024) 144 (Supplement 1): 3178.

https://doi.org/10.1182/blood-2024-193193

Published: 2024

Journal Articles

Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Blood (2024) 144 (Supplement 1): 2071.

https://doi.org/10.1182/blood-2024-208021

Published: 2024

NARROW

Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas

Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms

Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

A Phase 1 Study of CPX-351 Plus Gilteritinib in Relapsed or Refractory FLT3 -Mutated Acute Myeloid Leukemia

Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience

A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia

Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Marker in Myelodysplastic Syndromes

Prospective Evaluation of the Impact of Measurable Residual Disease (MRD) By Error Corrected Next-Generation Sequencing (NGS) with CPX-351 in Acute Myeloid Leukemia (AML)

Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies

The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS

Retrospective Real-World Analysis of Survival Outcomes in Patients with Myelofibrosis and New or Worsening Anemia Treated with Ruxolitinib in the United States

IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD)

Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin

Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes

Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)

Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia

Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis

Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only